Glofitamab in Real Life
This study is reviewing information from over 300 patients in France who received a medicine called Glofitamab for Large B-cell Lymphoma. This is a type of blood cancer. Glofitamab was given through a special program for patients who needed it. The aim is to see how effective and safe Glofitamab has been in real-life situations. The study will especially look at patients whose cancer came back or didn't respond to other treatments, including a specific therapy called CAR-T. Researchers want to confirm how well Glofitamab worked for these patients and figure out the best time to start this treatment.
At a glance
What is this study about?
This study is about a treatment called Glofitamab for a type of blood cancer known as Large B-cell Lymphoma. This particular study isn't testing a new treatment; instead, it's looking back at information from patients who have already received Glofitamab in France. These patients were part of a special program that allowed them to get the medicine when they really needed it.
The main goal is to understand how well Glofitamab worked for these patients and if there were any side effects. Researchers are particularly interested in patients whose cancer either returned after other treatments or didn't respond to those treatments, including a specific advanced therapy called CAR-T. By carefully reviewing these patient records, the study hopes to confirm how effective Glofitamab was for these challenging cases.
Ultimately, this research helps doctors learn more about Glofitamab's impact in everyday medical practice. It can also help them figure out the best time to give this treatment to patients who need it most, especially those with limited treatment options. This kind of 'real-world' information is very valuable because it shows how a medicine performs outside of tightly controlled clinical trials.
Key takeaways
- The study looks back at how Glofitamab worked for patients in France.
- It focuses on Large B-cell Lymphoma, a type of blood cancer.
- No new treatments or patient visits are involved.
- The goal is to understand the real-world effects and safety of Glofitamab.
- Data from patients whose cancer was hard to treat is especially important.
- This research helps improve future patient care.
Who may be eligible?
To be included in this study, you must have been a patient in France who received Glofitamab for a type of cancer called diffuse large B-cell lymphoma (DLBCL) before November 1st, 2024. You must have received at least one dose of Glofitamab and also had a pre-treatment dose of another medicine called Obinutuzumab.
You also need to be an adult, and you must have been told about the study and not said you didn't want your information to be used. The study is simply looking at your past medical records, so you won't need to do anything extra. There are no reasons listed that would prevent someone who meets these conditions from being included.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Did you receive Glofitamab in France for DLBCL before November 1st, 2024?
- Did you also receive Obinutuzumab before Glofitamab?
- Were you an adult when you received the treatment?
- Were you informed about the study and did not refuse to share your data?
What does participation involve?
If you meet the eligibility criteria, you won't need to do anything at all. This study is a 'retrospective analysis,' which means researchers are looking back at existing medical records and information that has already been collected. You won't have any appointments, assessments, or need to take any medication specifically for this study. There is no direct participation required from you and no set duration. The study only involves reviewing your past treatment history with Glofitamab.
Potential risks and benefits
Locations (30)
- CH Victor DupouyVerified postcodeArgenteuil, France· Recruiting
- CH d'Avignon - Hôpital Henri DufautVerified postcodeAvignon, France· Recruiting
- CH de la Côte BasqueVerified postcodeBayonne, France· Recruiting
- CHRU Besançon - Hôpital MinjozVerified postcodeBesançon, France· Recruiting
- Hopital D'Instruction Des Armees PercyVerified postcodeClamart, France· Recruiting
- Hopital Henri MondorVerified postcodeCréteil, France· Recruiting
- CHU de Dijon - Hôpital le BocageVerified postcodeDijon, France· Recruiting
- CH de DunkerqueVerified postcodeDunkirk, France· Recruiting
- CHU de Grenoble - Hôpital Albert MichallonVerified postcodeLa Tronche, France· Recruiting
- Hôpital de LibourneVerified postcodeLibourne, France· Recruiting
- CHRU de LILLE - Claude HuriezVerified postcodeLille, France· Recruiting
- Hopital Saint Vincent-de-PaulVerified postcodeLille, France· Recruiting
Common questions
What is Large B-cell Lymphoma?
It's a type of blood cancer that affects white blood cells called B-lymphocytes.
What is Glofitamab?
Glofitamab is a medication used to treat certain blood cancers, like Large B-cell Lymphoma.
Will I have to do anything if my information is used in this study?
No, you won't have to do anything. This study only looks at your existing medical records.
How does this study help doctors?
It helps doctors understand how well Glofitamab works for patients in real life, especially those with difficult-to-treat cancer.
Can I choose not to have my information included?
Yes, you can choose not to have your medical information included in this study if you did not agree to its collection.
How to find out more
PROJECT MANAGER
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.